Bayer invites you to view the fifth in this series of talks regarding Macular Degeneration: Focus on aflibercept - the latest evidence from clinical practice.

Professor Peter Kaiser is a Professor of Ophthalmology at the Cleveland Clinic Lerner College of Medicine and a staff surgeon in the Vitreoretinal Department at the Cole Eye Institute, Cleveland Clinic. He is the Founding Director of the Digital Optical Coherence Tomography Reading Center (DOCTR) at the Cole Eye Institute.


You will need to be registered and logged-on to access any of the activities listed below.
Accreditation: Not Accredited
 
Presentation: Focus on aflibercept: the latest evidence from clinical practice                                                                                                                                 
Access the Presentation 
 
View the Activity

PREVIOUS PRESENTATIONS BY BAYER
 
Translating clinical trial outcomes to real life with aflibercept 

 
Bayer invites you to view the third in this series of talks regarding Wet AMD.

Jean-François Korobelnik is Professor of Ophthalmology in Vitreoretinal Surgery and Head of the Ophthalmology Department at the University Hospital of Bordeaux, France.

You will need to be registered and logged-on to access any of the activities listed below.
 
Accreditation Not Accredited
Presentation: Translating clinical trial outcomes to real life with aflibercept 

Access the Presentation
 
View the Activity

 
 
The dual action of aflibercept

 
Bayer invites you to view the third in this series of talks regarding Wet AMD.

Professor Thomas Langmann from the Unversity Hospital of Cologne, Germany continues the discussion regarding treatments for Web AMD, in this video review of the dual action of aflibercept

You will need to be registered and logged-on to access any of the activities listed below.
 
Accreditation Not Accredited
Presentation: The dual action of aflibercept

Access the Presentation
 
View the Activity

 
 

The roles, values, pros and cons of Real Life Evidence
Associate Professor Alex Hunyor, MB BS (Hons), FRANZCO, FRACS, from the University of Sydney and Sydney Eye Hospital, Australia discusses the roles, values and pros and cons of Real Life Evidence
 
Accreditation Not Accredited
Presentation: The roles, values, pros and cons of Real Life Evidence

Access the Presentation
 
View the Activity

 
 
 

Treat-and-extend with anti-VEGFs: Data from clinical trials and the real world 
Mr Praveen Patel, Moorfields Eye Hospital, UK  Consultant Ophthalmologist |MA (Cantab), MB BChir (Cantab), FRCOphth, MD (Res) presents this, the second in the series of discussions regarding treatment of Wet AMD

 
Accreditation Not Accredited
Presentation: Treat-and-extend with anti-VEGFs: Data from clinical trials and the real world 

Access the Presentation
 
View the Activity


This content is brought to you in the interests of your Continued Medical Education by Bayer 



Disclaimer: The CME activity featured here is not endorsed in any way by the Medical Education Network .The  Medical Education Network cannot be held liable in  anyway  for the  mis-use  of or issues arising from the use of the information contained in this  third party  content

 


 
Bayer invites you to view the third in this series of talks regarding Wet AMD.

Professor Thomas Langmann from the Unversity Hospital of Cologne, Germany continues the discussion regarding treatments for Web AMD, in this video review of the dual action of aflibercept

You will need to be registered and logged-on to access any of the activities listed below.
 
Accreditation Not Accredited
Presentation: The dual action of aflibercept

Access the Presentation
 
View the Activity

 


The roles, values, pros and cons of Real Life Evidence
Associate Professor Alex Hunyor, MB BS (Hons), FRANZCO, FRACS, from the University of Sydney and Sydney Eye Hospital, Australia discusses the roles, values and pros and cons of Real Life Evidence
 
Accreditation Not Accredited
Presentation: The roles, values, pros and cons of Real Life Evidence

Access the Presentation
 
View the Activity

 
 
 

Treat-and-extend with anti-VEGFs: Data from clinical trials and the real world 
Mr Praveen Patel, Moorfields Eye Hospital, UK  Consultant Ophthalmologist |MA (Cantab), MB BChir (Cantab), FRCOphth, MD (Res) presents this, the second in the series of discussions regarding treatment of Wet AMD

 
Accreditation Not Accredited
Presentation: Treat-and-extend with anti-VEGFs: Data from clinical trials and the real world 

Access the Presentation
 
View the Activity


This content is brought to you in the interests of your Continued Medical Education by Bayer 



Disclaimer: The CME activity featured here is not endorsed in any way by the Medical Education Network .The  Medical Education Network cannot be held liable in  anyway  for the  mis-use  of or issues arising from the use of the information contained in this  third party  content

 

Bayer invites you to join Associate Professor Alex Hunyor, MB BS (Hons), FRANZCO, FRACS, from the University of Sydney and Sydney Eye Hospital, Australia discusses the roles, values and pros and cons of Real Life Evidence
 cols.


You will need to be registered and logged-on to access any of the activities listed below.
 
Presentation :  The roles, values,  pros and cons of Real Life Evidence
Access the Activity: 

 
View the Activity
 
  PREVIOUS PRESENTATIONS BY BAYER
   
Treat-and-extend with anti-VEGFs: Data from clinical trials and the real world 
 
Presented by: Mr Praveen Patel, Moorfields Eye Hospital, UK  Consultant Ophthalmologist |MA (Cantab), MB BChir (Cantab), FRCOphth, MD (Res)

 Not Accredited

  View the Activity
 


This content is brought to you in the interests of your Continued Medical Education by Bayer 



Disclaimer: The CME activity featured here is not endorsed in any way by the Medical Education Network .The  Medical Education Network cannot be held liable in  anyway  for the  mis-use  of or issues arising from the use of the information contained in this  third party  content

 

Globally, wet AMD is the 3rd cause of blindness after cataracts and glaucoma. While wet AMD comprises only 10% of the total spectrum of Macular Degeneration, it is responsible for approximately 90% of the loss of vision from the condition. In South Africa, the total incidence of AMD, wet and dry, in the 65+ age group, is in the region of 230,000 and affects all race groups

Bayer invites you to join Mr Praveen Patel, Moorfields Eye Hospital, UK  Consultant Ophthalmologist | MA (Cantab), MB BChir (Cantab), FRCOphth, MD (Res) as he discusses the latest Clinical Trial data in relation to anti-VEGFs and treat-and-extend protocols.


You will need to be registered and logged-on to access any of the activities listed below.
 
Accreditation: Not Applicable 
 
Presentation :  Treat-and-extend with anti-VEGFs: Data from clinical trials and the real world 


 
View the Activity
 
This content is brought to you in the interests of your Continued Medical Education by Bayer 



Disclaimer: The CME activity featured here is not endorsed in any way by the Medical Education Network .The  Medical Education Network cannot be held liable in  anyway  for the  mis-use  of or issues arising from the use of the information contained in this  third party  content

 

Rapid SSL Powered by LiveCAST, a VisualLive Solution
© Copyright 2020  I   Terms of Use   I   Disclaimer